<div class="WordSection1">

**<span style="color:black">From:<span style="mso-tab-count:1">                                            
</span></span>**<span style="color:black">Carpenter, Rachel</span>

**<span style="color:black">Sent:<span style="mso-tab-count:1">                                              
</span></span>**<span style="color:black">Tuesday, January 31, 2023 1:28
PM</span>

**<span style="color:black">To:<span style="mso-tab-count:1">                                                 
</span></span>**<span style="color:black">OH SPBM PA Pharmacist</span>

**<span style="color:black">Subject:<span style="mso-tab-count:1">                                        
</span></span>**<span style="color:black">Medication Guidance-
Sucraid</span>

<span style="color:
black"></span>

 

**<span style="color:black">Follow Up
Flag:<span style="mso-tab-count:1">                          
</span></span>**<span style="color:black">Follow up</span>

**<span style="color:black">Flag
Status:<span style="mso-tab-count:1">                                  
</span></span>**<span style="color:black">Flagged</span>

 

<span style="color:#333333">Please review the information provided below
and use for guidance.</span>

<span style="color:#333333;background:yellow;mso-highlight:
yellow">Suggested Medication Guidance:</span>

<span style="mso-fareast-font-family:&quot;Times New Roman&quot;;color:#333333">Diagnosis
of
</span><span style="mso-fareast-font-family:&quot;Times New Roman&quot;;
     color:black">Congenital sucrase-isomaltase
deficiency</span><span style="mso-fareast-font-family:&quot;Times New Roman&quot;"></span>

<span style="mso-fareast-font-family:&quot;Times New Roman&quot;;color:black">Must
be 5 months of age or
older</span><span style="mso-fareast-font-family:&quot;Times New Roman&quot;"></span>

<span style="mso-fareast-font-family:&quot;Times New Roman&quot;;color:black">Diagnosis
by:</span><span style="mso-fareast-font-family:&quot;Times New Roman&quot;"></span>

<span style="mso-fareast-font-family:&quot;Times New Roman&quot;;color:black">Small
bowel biopsy showing low sucrose activity and normal amounts of other
disaccharides **OR**
</span><span style="mso-fareast-font-family:&quot;Times New Roman&quot;"></span>

<span style="mso-fareast-font-family:&quot;Times New Roman&quot;;color:black"> Meeting
all of the following criteria:
</span><span style="mso-fareast-font-family:
       &quot;Times New Roman&quot;"></span>

  - <span style="mso-fareast-font-family:&quot;Times New Roman&quot;;color:black"> Stool
    pH\< 6
    </span><span style="mso-fareast-font-family:&quot;Times New Roman&quot;"></span>
  - <span style="mso-fareast-font-family:&quot;Times New Roman&quot;;color:black"> Increase
    in breath hydrogen of \>10ppm when challenged with sucrose after
    fasting
    </span><span style="mso-fareast-font-family:&quot;Times New Roman&quot;"></span>
  - <span style="mso-fareast-font-family:&quot;Times New Roman&quot;;color:black"> Negative
    lactose breath
    test</span><span style="mso-fareast-font-family:&quot;Times New Roman&quot;"></span>

<span style="mso-fareast-font-family:&quot;Times New Roman&quot;;color:black">Prescribed
by a pediatric gastroenterologist or genetic
specialist</span><span style="mso-fareast-font-family:&quot;Times New Roman&quot;"></span>

<span style="mso-fareast-font-family:&quot;Times New Roman&quot;">Dose
is within the FDA approved labeling</span>

 

 

 

  - <span style="mso-fareast-font-family:&quot;Times New Roman&quot;">Please
    see the attached for the Sucraid Package Insert and the below
    information from IPD analytics for information on Sucraid.</span>

 

<span class="image"></span>

 

**Use: Labeled Indications**

**Congenital sucrase-isomaltase deficiency: **Oral replacement therapy
in sucrase deficiency, as seen in congenital sucrase-isomaltase
deficiency (CSID).

 

<span style="font-size:10.5pt;font-family:&quot;Helvetica&quot;,sans-serif;
color:#333333">Congenital sucrase-isomaltase deficiency (CSID) is a
rare, inherited metabolic disorder characterized by the deficiency or
absence of the enzymes sucrase and isomaltase. This condition reduces
the ability of the patient to digest foods that contain sugars or
starches. The enzyme, sucrase-isomaltase, can be completely absent or in
very low levels of activity.</span>

<span style="font-size:10.5pt;font-family:&quot;Helvetica&quot;,sans-serif;
color:#333333">When the sucrase and isomaltase enzymes have low or
nonexistent activity, it can cause many gastrointestinal (GI) symptoms,
including diarrhea, gas, bloating, and abdominal pain. The symptoms of
CSID typically manifest in late infancy or early childhood. Onset of
symptoms is directly related to food consumption of the child. In
exclusively breast-fed babies, symptoms may not begin until
sucrose-containing foods are introduced into the diet. Some patients may
experience more mild symptoms, which can lead to the condition not being
diagnosed until adulthood. In addition, given the nonspecific symptoms
of CSID, the condition is often misdiagnosed as other functional GI
disorders, and CSID diagnosis is not confirmed until later on in the
course of the disease. Once CSID begins to be suspected, diagnosis can
be made through several mechanisms, including intestinal biopsy,
carbon-13 (C13) breath test, or through genetic testing.</span>

<span style="font-size:10.5pt;font-family:&quot;Helvetica&quot;,sans-serif;
color:#333333">A complicating factor in diagnosis is deciphering between
congenital sucrase-isomaltase deficiency and acquired/secondary
sucrase-isomaltase deficiency (SID). Acquired SID can result from
gastrointestinal disorders, such as celiac disease, Crohn's disease, or
even acute gastroenteritis. The symptoms of SID should resolve once the
underlying etiology is addressed. Currently, most diagnostic modalities
cannot decipher between the acquired and congenital forms, which
presents a complicating factor to health plans when approaching Sucraid
approval. Sucraid is indicated in the treatment of CSID specifically,
and efficacy has not been established in the acquired SID form.</span>

<span style="font-size:10.5pt;font-family:&quot;Helvetica&quot;,sans-serif;
color:#333333"></span>

 

**<span style="font-size:10.5pt;font-family:&quot;Helvetica&quot;,sans-serif;
color:#333333">Is there a gold standard for diagnosis that is able to
decipher between the congenital and acquired forms of sucrase-isomaltase
deficiency
(SID)?</span>**<span style="font-size:10.5pt;font-family:&quot;Helvetica&quot;,sans-serif;
color:#333333"></span>

<span style="font-size:10.5pt;font-family:&quot;Helvetica&quot;,sans-serif;mso-fareast-font-family:
     &quot;Times New Roman&quot;">There does not currently exist an
accessible, standard diagnostic test that is able to decipher between
the two forms. This presents a difficulty to payers, as this distinction
is important in issuing approval for Sucraid. **Sucraid is a treatment
specifically for CSID.** Since acquired SID occurs as a result of an
underlying pathology (e.g. celiac disease), patients are not often
treated for SID, but rather treatment of the underlying etiology is
targeted with the hope that it will cause resolution of SID.</span>

<span style="font-size:10.5pt;font-family:&quot;Helvetica&quot;,sans-serif;mso-fareast-font-family:
     &quot;Times New Roman&quot;">To our knowledge, there is only one
approach to truly decipher between the acquired and congenital forms,
and that is through sequencing the
entire *<span style="font-family:&quot;Helvetica&quot;,sans-serif">SI</span>* gene.
Conducting this is not commonplace in practice and is also not an
accessible option to all patients. In addition, to sequence an entire
gene is expensive, and may not be a necessary or cost-effective approach
to ensuring accurate diagnosis.</span>

<span style="font-size:10.5pt;font-family:&quot;Helvetica&quot;,sans-serif;mso-fareast-font-family:
      &quot;Times New Roman&quot;">CSID is caused by a mutation in
the *<span style="font-family:&quot;Helvetica&quot;,sans-serif">SI</span>* gene
on chromosome 3. CSID is an autosomal-recessive condition; however,
there are some heterozygotes that will experience symptoms, albeit less
severe. In North America, there appear to be four common mutations that
account for the majority of CSID cases.
A </span><span style="mso-fareast-font-family:
      &quot;Times New Roman&quot;">[<span style="font-size:10.5pt;font-family:&quot;Helvetica&quot;,sans-serif;
      color:#1155CC">study</span>](https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fjournals.lww.com%2Fjpgn%2FFulltext%2F2012%2F11002%2FFour_Mutations_in_the_SI_Gene_Are_Responsible_for.11.aspx&data=05%7C01%7Cchristopher.nguyen%40gainwelltechnologies.com%7C1bf0aec95fe34eee664508db03c154da%7Cc663f89cef9b418fbd3d41e46c0ce068%7C0%7C0%7C638107901132527610%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=NkjbbP9YwyRULTQQdOnH6Lj8vsx5zxRPjwgKJ9r61iI%3D&reserved=0)</span><span style="font-size:10.5pt;
      font-family:&quot;Helvetica&quot;,sans-serif;mso-fareast-font-family:&quot;Times New Roman&quot;"> found
that there is an 83% probability that an individual of European descent
with CSID will have one of these four mutations.</span>

<span style="font-size:10.5pt;font-family:&quot;Helvetica&quot;,sans-serif;mso-fareast-font-family:
      &quot;Times New Roman&quot;">When approaching genetic testing, is
important to distinguish whether the test sequences the
entire *<span style="font-family:&quot;Helvetica&quot;,sans-serif">SI</span>* gene
or whether it is just a panel of the four common mutations. If it is the
latter, there is a possibility that a true CSID patient will not be
identified. The price discrepancy between these two are quite
significant, with one </span><span style="mso-fareast-font-family:
      &quot;Times New Roman&quot;">[<span style="font-size:10.5pt;font-family:&quot;Helvetica&quot;,sans-serif;
      color:#1155CC">source</span>](https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fdepts.washington.edu%2Fmoleclab%2Favailable%2Fcsid.html&data=05%7C01%7Cchristopher.nguyen%40gainwelltechnologies.com%7C1bf0aec95fe34eee664508db03c154da%7Cc663f89cef9b418fbd3d41e46c0ce068%7C0%7C0%7C638107901132527610%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=mFu4r0f6DVpJsskKXf3Nwqqq5fstr%2BYOL3q9S4K5Woc%3D&reserved=0)</span><span style="font-size:10.5pt;
      font-family:&quot;Helvetica&quot;,sans-serif;mso-fareast-font-family:&quot;Times New Roman&quot;"> stating
the entire SI sequence costs approximately $8,000 and the panel of the
four common mutations costs around $1,000.</span>

  - <span style="font-size:10.5pt;font-family:&quot;Helvetica&quot;,sans-serif;mso-fareast-font-family:
           &quot;Times New Roman&quot;">The cost, availability, and
    accuracy of the genetic tests may impact payer decisions to require
    this as a diagnostic criterion. It does appear as though the gold
    standard for CSID diagnosis remains the small intestinal biopsy,
    even though it is unable to decipher between the types. If a request
    is sent to the plan for Sucraid when the patient has already had
    genetic testing conducted and CSID diagnosis ascertained, it would
    appear appropriate to accept this as an accurate means of diagnosis.
    But requiring such testing has many factors to consider, mentioned
    above.</span>
  - **<span style="font-size:10.5pt;font-family:&quot;Helvetica&quot;,sans-serif;mso-fareast-font-family:
           &quot;Times New Roman&quot;">It would appear reasonable to
    defer to the clinical judgment of the treating physician in regard
    to whether the SID is congenital or acquired. A criterion to
    implement may be to require this specification through attestation
    in the documentation for approval.</span>**

<div style="margin-top:15.0pt;margin-bottom:15.0pt">

<div>

<div>

<div>

<div>

<div class="MsoNormal">

<span style="mso-fareast-font-family:&quot;Times New Roman&quot;">
</span>

-----

</div>

</div>

</div>

</div>

</div>

</div>

**<span class="underline"><span style="font-size:10.5pt;font-family:&quot;Helvetica&quot;,sans-serif;
color:#333333;background:yellow;mso-highlight:yellow">Management
Opportunities and
Strategies</span></span>**<span style="font-size:10.5pt;font-family:
&quot;Helvetica&quot;,sans-serif;color:#333333;background:yellow;mso-highlight:yellow"></span>

  - <span style="font-size:10.5pt;font-family:&quot;Helvetica&quot;,sans-serif;
         mso-fareast-font-family:&quot;Times New Roman&quot;;background:yellow;mso-highlight:
         yellow">Most large payers do have criteria in place for
    Sucraid.</span>
  - **<span style="font-size:10.5pt;font-family:&quot;Helvetica&quot;,sans-serif;
         mso-fareast-font-family:&quot;Times New Roman&quot;;background:yellow;mso-highlight:
         yellow">The most common criterion is a diagnosis of CSID, with
    some payers specifically calling out secondary/acquired SID as a
    condition for which Sucraid is not covered.</span>**
  - <span style="font-size:10.5pt;font-family:&quot;Helvetica&quot;,sans-serif;
         mso-fareast-font-family:&quot;Times New Roman&quot;;background:yellow;mso-highlight:
         yellow">Other common criteria involve the confirmation of SID
    diagnosis through intestinal biopsy, C13 breath test, or meeting
    other specified criteria from
    the </span><span style="font-size:10.5pt;mso-fareast-font-family:
         &quot;Times New Roman&quot;;background:yellow;mso-highlight:yellow">Sucraid
    package
    insert</span><span style="font-size:10.5pt;font-family:&quot;Helvetica&quot;,sans-serif;
         mso-fareast-font-family:&quot;Times New Roman&quot;;background:yellow;mso-highlight:
         yellow"> (stool pH \<6, an increase in breath hydrogen \>10 ppm
    when challenged with sucrose after fasting, and a negative lactose
    breath test).</span>

<span style="font-size:10.5pt;font-family:&quot;Helvetica&quot;,sans-serif;
color:#333333;background:yellow;mso-highlight:yellow"></span>

 

<span style="color:black">References:</span>

<span style="color:black">ipdanalytics.com </span>

<span style="color:black">[https://www.sucraid.com/](https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.sucraid.com%2F&data=05%7C01%7Cchristopher.nguyen%40gainwelltechnologies.com%7C1bf0aec95fe34eee664508db03c154da%7Cc663f89cef9b418fbd3d41e46c0ce068%7C0%7C0%7C638107901132527610%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=jJ4M4A1UmataXv1upERThM7SJr6NJI%2FuxRXkKd%2FLqHA%3D&reserved=0)</span>

<span style="color:black">Lexi</span>

 

 

Thank you-

 

<span style="font-family:&quot;Arial&quot;,sans-serif">Rachel Carpenter
Rph</span>

<span style="font-family:&quot;Arial&quot;,sans-serif">Prior
Authorization Pharmacist</span>

<span style="font-family:&quot;Arial&quot;,sans-serif">Ohio SPBM</span>

<span style="font-family:&quot;Arial&quot;,sans-serif"></span>

 

<span style="font-family:&quot;Arial&quot;,sans-serif">M
1.513.233.1340</span>

<span style="font-family:&quot;Arial&quot;,sans-serif">T
1-833-491-0344</span>

[<span style="font-family:&quot;Arial&quot;,sans-serif">Rachel.Carpenter@gainwelltechnologies.com</span>](mailto:Rachel.Carpenter@gainwelltechnologies.com)<span style="font-family:&quot;Arial&quot;,sans-serif"></span>

<span style="font-family:&quot;Arial&quot;,sans-serif"></span>

 

<span style="font-family:&quot;Arial&quot;,sans-serif">Gainwell
Technologies</span>

<span style="font-family:&quot;Arial&quot;,sans-serif">5475 Rings
RD</span>

<span style="font-family:&quot;Arial&quot;,sans-serif">Atrium II North
Tower, Suite 125</span>

<span style="font-family:&quot;Arial&quot;,sans-serif">Dublin, OH
43017-7565</span>

<span style="font-family:&quot;Arial&quot;,sans-serif"></span>

 

<span style="font-family:&quot;Arial&quot;,sans-serif">Gainwelltechnologies.com</span>

<span style="font-family:&quot;Arial&quot;,sans-serif"></span>

 

 <span style="font-family:&quot;Arial&quot;,sans-serif"><span class="image"></span></span>

 

</div>
